TransMedics Group, Inc. (NASDAQ:TMDX) Position Cut by Ensign Peak Advisors Inc

Ensign Peak Advisors Inc lessened its holdings in shares of TransMedics Group, Inc. (NASDAQ:TMDX) by 13.1% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 149,104 shares of the company’s stock after selling 22,405 shares during the period. Ensign Peak Advisors Inc owned 0.45% of TransMedics Group worth $22,458,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds also recently modified their holdings of TMDX. Fidelis Capital Partners LLC acquired a new position in shares of TransMedics Group during the 1st quarter valued at $35,000. International Assets Investment Management LLC purchased a new position in TransMedics Group in the 2nd quarter worth about $47,000. J.Safra Asset Management Corp lifted its position in shares of TransMedics Group by 649.2% in the 2nd quarter. J.Safra Asset Management Corp now owns 442 shares of the company’s stock valued at $67,000 after acquiring an additional 383 shares in the last quarter. Signaturefd LLC raised its stake in TransMedics Group by 26.6% during the 2nd quarter. Signaturefd LLC now owns 443 shares of the company’s stock valued at $67,000 after purchasing an additional 93 shares during the period. Finally, Amalgamated Bank boosted its position in TransMedics Group by 6.7% during the 2nd quarter. Amalgamated Bank now owns 1,114 shares of the company’s stock worth $168,000 after acquiring an additional 70 shares during the period. Institutional investors own 99.67% of the company’s stock.

Insiders Place Their Bets

In related news, insider Tamer I. Khayal sold 2,958 shares of TransMedics Group stock in a transaction dated Thursday, August 1st. The stock was sold at an average price of $156.77, for a total value of $463,725.66. Following the completion of the transaction, the insider now directly owns 20,843 shares of the company’s stock, valued at $3,267,557.11. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In related news, insider Tamer I. Khayal sold 2,958 shares of the firm’s stock in a transaction that occurred on Thursday, August 1st. The shares were sold at an average price of $156.77, for a total value of $463,725.66. Following the completion of the sale, the insider now owns 20,843 shares of the company’s stock, valued at $3,267,557.11. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Nicholas Corcoran sold 10,000 shares of the stock in a transaction on Tuesday, August 27th. The shares were sold at an average price of $176.02, for a total value of $1,760,200.00. Following the completion of the transaction, the insider now owns 21,105 shares in the company, valued at $3,714,902.10. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 61,247 shares of company stock valued at $9,650,880. 7.00% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on the company. Morgan Stanley lifted their price target on TransMedics Group from $104.00 to $145.00 and gave the company an “equal weight” rating in a report on Monday, July 15th. Cantor Fitzgerald started coverage on TransMedics Group in a research note on Thursday, June 6th. They issued an “overweight” rating and a $161.00 price objective on the stock. Canaccord Genuity Group raised their target price on TransMedics Group from $117.00 to $169.00 and gave the company a “buy” rating in a report on Thursday, August 1st. Piper Sandler upped their price target on TransMedics Group from $170.00 to $180.00 and gave the stock an “overweight” rating in a report on Thursday, August 1st. Finally, Oppenheimer increased their price target on shares of TransMedics Group from $125.00 to $200.00 and gave the company an “outperform” rating in a report on Thursday, August 1st. One research analyst has rated the stock with a hold rating and eight have issued a buy rating to the stock. Based on data from MarketBeat.com, TransMedics Group currently has a consensus rating of “Moderate Buy” and a consensus price target of $171.44.

TransMedics Group Stock Performance

NASDAQ TMDX opened at $165.00 on Monday. The company has a quick ratio of 8.48, a current ratio of 9.37 and a debt-to-equity ratio of 2.67. The stock has a market cap of $5.43 billion, a P/E ratio of -485.29 and a beta of 1.99. TransMedics Group, Inc. has a twelve month low of $36.42 and a twelve month high of $177.37. The company’s 50-day simple moving average is $155.65 and its 200 day simple moving average is $129.63.

TransMedics Group (NASDAQ:TMDX) last issued its quarterly earnings data on Wednesday, July 31st. The company reported $0.35 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.21 by $0.14. The company had revenue of $114.30 million during the quarter, compared to analysts’ expectations of $98.84 million. TransMedics Group had a return on equity of 15.98% and a net margin of 0.84%. The business’s revenue was up 117.7% on a year-over-year basis. During the same period last year, the business earned ($0.03) earnings per share. As a group, research analysts forecast that TransMedics Group, Inc. will post 1.23 earnings per share for the current fiscal year.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.